ECSP014055A - Activadores de glucoquinasa que contienen hidantoina - Google Patents

Activadores de glucoquinasa que contienen hidantoina

Info

Publication number
ECSP014055A
ECSP014055A EC2001004055A ECSP014055A ECSP014055A EC SP014055 A ECSP014055 A EC SP014055A EC 2001004055 A EC2001004055 A EC 2001004055A EC SP014055 A ECSP014055 A EC SP014055A EC SP014055 A ECSP014055 A EC SP014055A
Authority
EC
Ecuador
Prior art keywords
glucoquinase
activators containing
containing hydantoin
hydantoin
activators
Prior art date
Application number
EC2001004055A
Other languages
English (en)
Inventor
Robert Alan Goodnow
Kang Le
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP014055A publication Critical patent/ECSP014055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de hidantoína que son activos como activadores de la glucoquinasa para aumentar la secreción de insulina, lo cual los hace útiles para el tratamiento de la diabetes tipo II.
EC2001004055A 2000-05-03 2001-05-03 Activadores de glucoquinasa que contienen hidantoina ECSP014055A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20149800P 2000-05-03 2000-05-03

Publications (1)

Publication Number Publication Date
ECSP014055A true ECSP014055A (es) 2002-01-25

Family

ID=22746054

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004055A ECSP014055A (es) 2000-05-03 2001-05-03 Activadores de glucoquinasa que contienen hidantoina

Country Status (20)

Country Link
US (2) US6583288B2 (es)
EP (1) EP1280801B1 (es)
JP (1) JP3842131B2 (es)
KR (1) KR100505312B1 (es)
CN (1) CN1209361C (es)
AR (1) AR034253A1 (es)
AT (1) ATE304011T1 (es)
AU (2) AU5227001A (es)
BR (1) BR0110492A (es)
CA (1) CA2407428C (es)
DE (1) DE60113247T2 (es)
DK (1) DK1280801T3 (es)
EC (1) ECSP014055A (es)
ES (1) ES2248309T3 (es)
MX (1) MXPA02010746A (es)
PE (1) PE20011313A1 (es)
PT (1) PT1280801E (es)
UY (1) UY26689A1 (es)
WO (1) WO2001083478A2 (es)
ZA (1) ZA200208370B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1209361C (zh) * 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2374236C2 (ru) 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
JP2006509774A (ja) 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) * 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
EP1737870A1 (en) 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
CN1960995B (zh) 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
KR20090006885A (ko) * 2004-08-17 2009-01-15 에프. 호프만-라 로슈 아게 치환 히단토인
WO2006031491A2 (en) * 2004-09-09 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
ATE464305T1 (de) 2004-09-13 2010-04-15 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
CA2614518A1 (en) 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
FR2894962B1 (fr) * 2005-12-20 2008-03-14 Pharmamens Sarl Hydantoines a action insulinotropique
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
CN101687800B (zh) * 2007-03-07 2012-03-21 杏林制药株式会社 葡糖激酶活化物质
CA2680307A1 (en) * 2007-03-12 2008-09-18 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US7557221B2 (en) 2007-08-16 2009-07-07 Hoffman-La Roche Inc. Substituted hydantoins
MX2010006331A (es) * 2007-12-20 2010-07-05 Hoffmann La Roche Hidantoinas sustituidas como inhibidores de cinasa mek.
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
MY163114A (en) 2008-04-28 2017-08-15 Kyorin Seiyaku Kk Cyclopentylacrylamide derivative
TWI445707B (zh) 2008-05-16 2014-07-21 Takeda California Inc 葡萄糖激酶活化劑
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
EA201270217A1 (ru) 2009-07-31 2012-09-28 Кадила Хелзкэр Лимитед Замещенные бензамидные производные в качестве активаторов глюкокиназы (гк)
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
ES2671881B1 (es) * 2016-11-11 2019-03-25 Consejo Superior Investigacion Procedimiento de obtencion de polimeros con grupos isocianato
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
EP4161640A4 (en) 2020-06-08 2024-01-17 vTv Therapeutics LLC Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
CN1209361C (zh) * 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂

Also Published As

Publication number Publication date
PE20011313A1 (es) 2001-12-28
KR100505312B1 (ko) 2005-08-04
CN1209361C (zh) 2005-07-06
US20030225286A1 (en) 2003-12-04
DE60113247D1 (de) 2005-10-13
EP1280801A2 (en) 2003-02-05
BR0110492A (pt) 2003-04-08
US6583288B2 (en) 2003-06-24
CA2407428A1 (en) 2001-11-08
JP3842131B2 (ja) 2006-11-08
AU2001252270B2 (en) 2005-12-15
CN1427838A (zh) 2003-07-02
CA2407428C (en) 2010-02-02
JP2003531905A (ja) 2003-10-28
US20010056191A1 (en) 2001-12-27
EP1280801B1 (en) 2005-09-07
UY26689A1 (es) 2001-11-30
WO2001083478A3 (en) 2002-05-16
MXPA02010746A (es) 2003-03-10
KR20020093120A (ko) 2002-12-12
WO2001083478A2 (en) 2001-11-08
DE60113247T2 (de) 2006-06-22
ATE304011T1 (de) 2005-09-15
US6784298B2 (en) 2004-08-31
AR034253A1 (es) 2004-02-18
PT1280801E (pt) 2005-11-30
DK1280801T3 (da) 2006-01-23
AU5227001A (en) 2001-11-12
ES2248309T3 (es) 2006-03-16
ZA200208370B (en) 2004-01-26

Similar Documents

Publication Publication Date Title
ECSP014055A (es) Activadores de glucoquinasa que contienen hidantoina
UY26694A1 (es) Activadores de fenil glucocinasa para - arilo o hetero sustituidos
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
ECSP014054A (es) Activadores de glucoquinasa alquinil fenil heteroaromatica
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
UY27069A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
UY26695A1 (es) Activadores para amino sustituidos de la fenilamida glucoquinasa
GT200300096A (es) Activadores de cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
SV2009003235A (es) Triazoles biciclicos como moduladores de la proteina cinasa ref. x-18476m
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
PA8493701A1 (es) Compuestos para tratar la obesidad
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
HN2003000422A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
CR6935A (es) Agentes del receptor b3-adrenergico y usos de los mismos
NO20091260L (no) Kombinasjonsbehandling for diabetes mellitus
CO6382118A2 (es) Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.